Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article argues that psychoactive drugs are often beneficial in treating dermatological conditions with psychiatric or psycho-emotional components but does not present new clinical evidence.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This review discusses the wide range of drugs potentially causing reversible or irreversible hair loss and emphasizes the difficulty of diagnosing drug-induced alopecia without withdrawal of the suspected medication; it reports no new clinical findings.

This review covers medication-induced telogen effluvium with a focus on systemic retinoids, antifungal agents, and psychotropic medications, and reports no new clinical results.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

This study found that among dermatologists surveyed, 51.9% routinely prescribe the psychotropic agent Doxepin for treating geriatric patients with psycho cutaneous conditions.

This study reported that various medications, including known agents like finasteride and testosterone as well as unexpected ones like certain psychotropics and statins, are linked to male infertility cases in the Vigibase database.

This review explores cannabigerol (CBG) as a potential therapeutic agent with various pharmacological activities but reports no new clinical results, emphasizing the need for further research on its efficacy and safety.

This article reviews drug-induced pigmentation and reports no new clinical findings, highlighting difficulty in confirming drug associations due to factors like delayed onset and polypharmacy.

This case report describes hair loss associated with olanzapine use, which resolved after discontinuation of the drug, highlighting potential reversible alopecia with atypical antipsychotics.

This article discusses common dermatologic side effects of psychopharmacologic agents such as eruptions, urticaria, and photosensitivity, but it reports no new research findings.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

This review discusses the complex relationship between psychotropic medications and the skin, focusing on cutaneous side effects, dermatologic uses, and psychiatric disorders with skin manifestations, but reports no new findings.

This paper reviews the growing use of psychotropic drugs in dermatology due to the link between mental states and skin conditions but does not present new clinical findings.

This review examines alopecia as a side effect of psychotropic medications, noting that it is typically reversible after stopping the drug, but it reports no new results.

This review explores how psychotropic medications can cause a range of skin reactions, from mild to life-threatening, and emphasizes the importance of monitoring for these adverse effects early in treatment.

In this large multicenter study, severe hair loss related to psychotropic drug treatment was very rare but occurred more frequently in female patients, with valproic acid showing the highest risk.

This review describes psychotropic drug-related hair loss as a possible but uncommon side effect, with resolution typically achieved by discontinuing the medication, and emphasizes clinician-patient discussions for managing the condition.

This review discusses the range and management of adverse cutaneous reactions to psychotropic medications and emphasizes the need for awareness among clinicians, concluding with a call for careful monitoring and patient education.

This review found that patients taking antiandrogens, 5 alpha-reductase inhibitors, and spironolactone have an increased risk of developing gynecomastia, potentially due to hormonal changes.

In this study of transgender and gender-diverse adults, the researchers observed that one-third of those on psychotropic medications within two years of starting hormone therapy experienced psychotropic polypharmacy, with a significantly higher likelihood of potential drug-hormone interactions in this group.

Over 40% of postmenopausal women experience hair loss, with treatments aiming to stop further loss and possibly thicken hair.

This chapter discusses the mechanisms, presentation, course, differential diagnosis, and treatment of drug-induced skin reactions and reports no new clinical results.

This analysis examines acne vulgaris using an integrative approach, highlighting its links with psychopathology, lifestyle, and diet, but reports no new results.

This review discusses the link between medication use and hair loss and emphasizes the need for further research into other potential causes, reporting no new clinical results.

This article reviews the interconnectedness of the skin and nervous system and discusses various treatment options for psychophysiological skin disorders, reporting no new clinical results.

This article discusses the diagnosis and management of allergic dermatoses in dogs, focusing on clinical diagnosis, complementary tests, and various treatment strategies, but it reports no new results.

This document by the AACE and AES provides a 2015 summary of best practices for diagnosing and managing PCOS, emphasizing clinical assessment and treatment options but reports no new clinical results.

This review highlights that while lifestyle changes may help with many ovulatory disorders, oocyte donation is considered a viable option for patients who cannot undergo ovulation induction; it reports no new results.